Recommended: 3 × 10 ml cfDNA blood tubes. Ascites, cerebrospinal fluid, or pancreatic-cyst fluid can be reviewed case by case.
TUMOR DIAGNOSTICS
CancerDetect
Uses duplex-UMI sequencing to detect selected low-frequency tumor variants in circulating cell-free DNA when tissue is unavailable or serial blood monitoring is useful.
Selected hotspots/regions in 31 genes plus fusions in 6 genes, raw depth around 50,000–100,000×, and a referenced nominal allele-frequency threshold from 0.25%.
Detected actionable variants, variant fractions, potential treatment relevance, and longitudinal comparison when serial samples are provided.
Confirmed after sample and clinical review.
CLINICAL VALUE
Where this test is strongest
✓Non-invasive cfDNA workflow
✓Duplex-UMI error suppression
✓31 selected genes plus 6 fusion genes
✓Serial progression display
✓Referenced detection from 0.25% variant allele frequency
LIMITATIONS
What must remain visible
!This is hotspot/selected-region analysis, not full sequencing of all 31 genes.
!Some tumors shed little or no ctDNA, so a negative blood result cannot rule out tumor variants.
!Performance varies with tumor burden, site, treatment, and sample handling.
GENE & ANALYTICAL SCOPE
33 published genes
The genes are included at selected actionable regions; they should not be interpreted as complete-gene coverage.
Selected DNA regions31 published genes+
31 genes with selected actionable hotspots or regions, not complete-gene analysis.
AKT1ALKARBRAFCDKN2ACTNNB1EGFRERBB2ERBB3ESR1FGFR1FGFR2FGFR3GNA11GNAQGNASH3-3AHRASIDH1IDH2JAK2KITKRASMETNRASPDGFRAPIK3CAPTENRETTERTTP53
Fusion genes6 published genes+
6 genes assessed for selected fusions.
ALKRETROS1FGFR2FGFR3NTRK1
BEFORE ORDERING
Confirm the current laboratory specification.
The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.